| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-05-10 | Sistemic Ltd (UK) Roslin Cells Ltd (UK) | new technologies for the standardisation of the manufacture of stem cells for their use in cell therapy and drug development screening | Collaboration Promotion | |||
| 2011-05-10 | Phylogica (Australia) Pepscan Therapeutics (The Netherlands) | therapeutic phylomer drug candidates | R&D |
|||
| 2011-05-09 | FORMAC Pharmaceuticals (Belgium) W. R. Grace & Co.’s Discovery Sciences (USA) | new silica based drug products | Collaboration | Drug delivery | ||
| 2011-05-09 | Kancera (Sweden) Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center (USA) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2011-05-09 | Heptares Therapeutics (UK) Shire Pharmaceuticals (UK) | novel adenosine A2A antagonist | CNS diseases | Licensing |
CNS diseases | Licensing agreement |
| 2011-05-05 | Almirall (Spain) Nycomed (Switzerland) | roflumilast | chronic obstructive pulmonary disease (COPD) | commercialisation |
Respiratory diseases | Commercialisation agreement |
| 2011-05-04 | Oxford Biomedica( UK) Pfizer (USA- NY) | therapeutic products which target the Oxford Biomedica’s proprietary 5T4 tumour antigen | licensing |
Cancer - Oncology | Licensing agreement | |
| 2011-05-04 | Algeta (Norway) Affibody (Sweden) | Affibody® molecules and Albumod™ for two targets within the oncology field, HER2 and PDGFR-Beta | Licensing |
Cancer Oncology | Licensing agreement | |
| 2011-05-04 | Cenix Biosciences (Germany) Janssen Pharmaceutica (J&J-USA) | in vivo siRNA delivery technology | R&D |
CNS diseases | R&D agreement | |
| 2011-05-04 | Debiopharm (Switzerland) Yale University (USA) | Debio 1036 | licensing |
Autoimmune diseases - Inflammatory diseases | Licensing agreement | |
| 2011-05-04 | Angel Biotechnology (UK) Pathfinder Cell Therapy (USA) | newly discovered mammalian cell type capable of stimulating damaged tissues to regenerate | manufacturing |
Production agreement | ||
| 2011-05-02 | Dyadic (USA) Engen Bio (USA) Sanofi Pasteur (France) | undisclosed | R&D |
R&D agreement | ||
| 2011-04-28 | Flamel Technologies (France) Undisclosed specialty pharmaceutical company | two molecules for pain indications | pain | Licensing |
CNS diseases | Licensing agreement |
| 2011-04-27 | Affitech (Denmark) Cancer Research Technology (UK) | therapeutic antibodies that recognize and block the function of CCR4* AT008 program | solid tumors | licensing |
Cancer - Oncology | Licensing agreement |
| 2011-04-27 | Affitech (Denmark) University of Texas Southwestern Medical Center (USA) | AT001/r84 | Collaboration |
Collaboration agreement | ||
| 2011-04-27 | Beactica (Sweden) Janssen Research & Development - J&J (Belgium-USA) | Sprint™ | undisclosed | R&D |
undisclosed | R&D agreement |
| 2011-04-26 | Vivalis (France) SC World (Japan) Toyama Prefecture (Japan) | high-throughput screening (HTS) single-cell antibody discovery technology | Licensing |
Licensing agreement | ||
| 2011-04-26 | Karo Bio (Sweden) Alkem (India) | eprotirome | heterozygous familial hypercholesterolemia | collaboration licensing |
Cardiovascular diseases - Genetic diseases - Metabolic diseases | Licensing agreement |
| 2011-04-26 | Kuros Biosurgery (Switzerland) Baxter (USA) | KUR-111, KUR-113, KUR-115 | licensing |
Traumatology | Licensing agreement | |
| 2011-04-26 | Rhenovia Pharma (France) Sodiaal-Candia (France) | R&D |
R&D agreement |
